Project Grant R41HL178144
Award Date
4/1/25
Completion Date
3/31/26
Dollars Obligated
$568K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a precision medicine approach to red blood cell (RBC) transfusion therapy for sickle cell disease (SCD). The primary goal is to prevent alloimmunization, a major complication of RBC transfusions in SCD patients, by providing RH genotype-matched donor RBCs. The $834,499 award to The Children's Hospital of Philadelphia will fund...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $265,347 Project Grant to Functional Fluidics Inc. to develop and validate a point-of-care (POC) device for assessing red blood cell sickling in sickle cell disease (SCD) patients. The goal is to create a simple, standalone, and potentially CLIA-waived POC system that can measure oxygen-induced sickling to assist in monitoring SCD patient condition and...
The federal Project Grant award R43HL172515 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award of $295,963 aims to develop a modernized whole blood storage platform that reduces initial oxygen content and maintains an oxygen-managed environment during refrigerated storage. This is intended to provide higher quality red blood cells for improved oxygen delivery and shock reversal, while maintaining...
This federal Project Grant award of $590,283 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the robustness and reproducibility of human pluripotent stem cell (hPSC) differentiation into cardiomyocytes (CMs) through feedback-controlled closed-loop manufacturing processes. The key goals are to:
Identify 2D CM differentiation failure modes through integrated single-cell transcriptomics and epigenomics...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $128,100.00 to the New York Blood Center, Inc. to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The goal is to address barriers to equitable access to SCD gene therapy, which often requires extensive leukapheresis and myeloablative conditioning. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) is providing $2,275,731 to the Icahn School of Medicine at Mount Sinai to conduct research on deriving hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs). The goal is to understand the transcriptional and signal requirements for generating this unique population of CD34+ progenitor cells that can home to bone marrow and...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $234,000.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to develop hemostatic red blood cells (T-RBCs) targeted to collagen and fibrin for treating non-compressible hemorrhage. The key objectives are to: 1) engineer the T-RBCs and test their binding efficiency in vitro; 2) measure...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate how red blood cells (RBCs) contribute to inflammation and multi-organ dysfunction associated with cardiopulmonary bypass (CPB) procedures during pediatric heart surgeries. The $2,543,734 award to Seattle Children's Hospital, effective May 1, 2024 through April 30, 2028, will fund experiments to uncover the molecular mechanisms by which...
This $294,063 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development and demonstration of a high-volume manufacturing technology for microfluidic oxygenators. The goal is to produce a safer and simpler treatment option for respiratory failure, which represents a significant and growing healthcare challenge. The funding will be used to: 1) define the target product profile and optimize the design for...